Armistice Capital, LLC has filed its 13F form on May 15, 2024 for Q1 2024 where it was disclosed a total value porftolio of $7.34 Billion distributed in 337 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Ptc Therapeutics, Inc. with a value of $197M, Neurocrine Biosciences Inc with a value of $141M, Incyte Corp with a value of $125M, Supernus Pharmaceuticals, Inc. with a value of $122M, and Cytokinetics Inc with a value of $107M.

Examining the 13F form we can see an increase of $275M in the current position value, from $7.07B to 7.34B.

Armistice Capital, LLC is based out at New York, NY

Below you can find more details about Armistice Capital, LLC portfolio as well as his latest detailed transactions.

Portfolio value $7.34 Billion
ETFs: $3.73 Billion
Healthcare: $2.46 Billion
Consumer Defensive: $399 Million
Consumer Cyclical: $369 Million
Technology: $260 Million
Basic Materials: $37.4 Million
Communication Services: $35.9 Million
Energy: $23 Million
Other: $23.9 Million

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History

Summary

  • Portfolio
  • No. of Stocks 337
  • Current Value $7.34 Billion
  • Prior Value $7.07 Billion
  • Filing
  • Period Q1 2024
  • Filing Date May 15, 2024
  • Form Type 13F-HR
  • Activity in Q1 2024
  • New Purchases 139 stocks
  • Additional Purchases 85 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 83 stocks
Track This Portfolio

Track Armistice Capital, LLC Portfolio

Follow Armistice Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Armistice Capital, LLC with notifications on news.